In this issue:
Real-world OS and characteristics in ER–/low, HER2– breast cancer treated as TNBC
Preventing alpelisib-related hyperglycaemia with metformin
Neoadjuvant anlotinib + taxane-lobaplatin for stage II–III TNBC
Long-term outcomes of high-risk ILC vs. IDC
Adjuvant aspirin in breast cancer
Taselisib + HER2-directed therapies for advanced HER2+ breast cancer
Palbociclib + endocrine therapy when relapse risk is high after neoadjuvant chemotherapy
Ribociclib-induced cutaneous adverse events
Neoadjuvant tucidinostat + exemestane in early hormone receptor+, HER2– breast cancer
Predicting endocrine responsiveness in ER+, HER2– metastatic breast cancer
Please login below to download this issue (PDF)